Abingworth life science investment
 


John Shields
Principal, Science and Technology

John Shields
has 13 years of operational experience in life science companies. He joined Abingworth in 2001 from Cantab Pharmaceuticals where he was Senior Vice-President, Research. He had a strong role in business development and played a significant part in the in-licensing of new products and technologies to the firm. Prior to Cantab, he was at the Glaxo Institute for Molecular Biology in Geneva, Switzerland. From 1982 to 1988, he held research positions at the Institute of Child Health, the University of London, UK. John has a PhD in Immunology from the University of Glasgow. He has published more than 30 papers in peer-reviewed journals including Science. At Abingworth, John is involved with scientific evaluation of new and existing investments and works closely with UK universities and early-stage companies.